Phase I – Other

1,064 trials 249 recruiting

Filter these 1,064 trials by condition, country, sponsor and more.

Open in Search →

A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN-049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH M… Recruiting

2023-506572-27-00 Acute Myeloid Leukemia (AML) with Measurable Residual D 2024-01-12
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B… Recruiting

2022-503114-23-00 Breast Cancer 2023-12-19
Performance and prognostic value of 68Ga-FAPI PET/CT in non-small cell lung cancer (NSCLC) Recruiting

2023-503985-21-00 Non small cell lung cancer 2023-11-07
PARP-PET in solid tumors Recruiting

2022-502918-87-00 cancer patients 2023-10-02
Implementation and evaluation of Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) for the treatment of patients with malignant pleural… Recruiting

2023-503297-20-00 Malignant pleural effusion 2023-09-15
A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or… Recruiting

2022-501508-82-00 Solid Tumors 2023-08-23
An open-label, multicentre, rollover study to evaluate safety and antineoplastic activity of OATD-02 in patients with selected advances and/… Recruiting

2024-513006-61-00 Advanced and/or metastatic solid tumours (colorectal ca 2023-08-23
Pharmacokinetics and penetrability of clindamycin and cefalexin into bone tissue Recruiting

2024-517873-25-00 Patients undergoing planned amputation surgery of any p 2023-08-03
A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients with Newly Diagnosed Glioblastoma Recruiting

2024-515466-13-00 Glioblastoma multiforme (GBM) 2023-06-28
A study of different dose levels of FluBHPVE6E7 or placebo in women infected with the virus Human Papilloma Type 16 (HPV 16). Recruiting

2024-515535-30-00 Treatment of human papilloma virus (HPV) associated inf 2023-06-22
A model of a sterile, self-limiting, acute inflammatory response in healthy volunteers using lipopolysaccharides – a platform trial Recruiting

2024-518768-11-02 Healthy volunteers 2023-05-19
Single dose pharmacokinetics of selected antibiotics in plasma and soft tissues of healthy volunteers. Recruiting

2024-518260-13-00 Healthy volunteers 2023-05-15
EPI/HIS-trial Recruiting

2024-517017-33-00 No medical condition, it is a study in healthy voluntee 2023-04-04
Individualized Systems Medicine strategy to target cancer stem cells in patients with recurrent Glioblastoma (ISM-GBM) Recruiting

2023-510214-11-00 Recurrent Glioblastoma 2023-03-21
Monocentric phase 1 dose-escalation study of siltuximab in combination with idarubicin and cytarabine chemotherapy in patients with poor pro… Recruiting

2022-501171-14-00 adult patients with acute myeloblastic leukemia (AML) o 2023-03-13
KF2022#1 trial: The effect of fecal microbiota transplantation on CYP enzyme activities Recruiting

2024-518312-40-00 Irritable bowel syndrome 2023-01-05
DMT in healthy subjects Recruiting

2024-518020-68-00 Stroke 2022-11-15
Phase 1/1b study to assess the drug OBT076 in patients with recurrent and/or metastatic CD205-positive solid tumors Recruiting

2024-511884-27-00 CD205+ve recurrent and/or metastatic tumor types includ 2022-11-09
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple M… Recruiting

2023-506247-42-00 Relapsed/Refractory Multiple Myeloma 2022-08-17
A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o… Recruiting

2024-516331-27-00 Participants with BRAF and/or NRAS mutation positive tu 2022-06-10
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer … Recruiting

2024-512089-32-00 Relapsed or Refractory B-cell Non-Hodgkin Lymphoma 2022-03-28
Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors Recruiting

2024-513007-14-00 locally advanced or metastatic, well-differentiated gas 2022-03-24
Phase 1 trial of trametinib and gilteritinib for the treatment of relapsed or refractory acute leukemia patients Recruiting

2024-518301-18-00 Relapsed and/or refractory acute lymphoblastic (ALL) or 2022-01-28
A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractor… Recruiting

2023-503404-89-00 Relapsed or Refractory Multiple Myeloma R/R MM 2021-12-08